Company / Depreciation & Amortization
Theravance Biopharma, Inc. Depreciation & Amortization History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$3.3M
FY2022
5-year range
$3.3M / $3.3M
FY2018-FY2022
Trend
-
vs FY2021
Sector context
#85 of 168
Health Care
What the data says
At $3M, Theravance Biopharma, Inc.'s depreciation & amortization ranks #84 of 168 in the Health Care sector. Depreciation & Amortization returned to growth in FY2022 after 2 years of decline, reaching $3M.
Based on SEC 10-K filings.
$3M in FY2022 with a 5-year CAGR of -3.9%.
Increased from $3M to $3M over the past 4 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +9.7%
- 5-Year CAGR
- -3.9%
- 10-Year CAGR
- -
Sector benchmark
#84 of 168 in Health CareTop 49% of 168This company $3.3M Sector average $212.9M
▼
-98.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.9%, indicating a declining trend.
- Ranks #85 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2017.
- Lowest depreciation & amortization in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $3.3M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | $2.5M | -19.8% |
| FY2018 | $3.1M | -22.5% |
| FY2017 | $4.0M | +29.1% |
| FY2016 | $3.1M | +17.6% |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026